Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials

RTTNews | vor 123 Tagen
Stocktwits
Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials

(RTTNews) - Eli Lilly and Co. (LLY) announced Tuesday a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.

Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape. The misuse and overuse of antimicrobials in humans, animals and plants are the main drivers in the development of drug-resistant pathogens, magnifying this threat to global health.

This collaboration with OpenAI supports Lilly's earlier commitment to fighting drug-resistant pathogens through its Social Impact Venture Capital Portfolio.

In 2020, the portfolio committed $100 million to the AMR Action Fund, aiming to provide patients with two to four new antibiotics by 2030 and contribute the next line of defense against multi-drug-resistant pathogens.

In April 2023, the AMR Action Fund announced its latest investments in biotech companies targeting a range of infections.

Tags: LLY
Stocktwits
read more
Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook

Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook

Drugmaker Eli Lilly reported Thursday a net profit for the second quarter that surged 68 percent from last year, reflecting strong Mounjaro, Zepbound and Verzenio sales as well as higher realized prices. Both adjusted earnings per share and revenues topped analysts' expectations. The company also raised its guidance for the full-year 2024.
RTTNews | vor 79 Tagen
Eli Lilly Again Boosts FY24 Outlook - Update

Eli Lilly Again Boosts FY24 Outlook - Update

While reporting financial results for the second quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound, as well as the company's non-incretin medicines.
RTTNews | vor 79 Tagen
Eli Lilly CFO Anat Ashkenazi Resigns

Eli Lilly CFO Anat Ashkenazi Resigns

Eli Lilly and Co. (LLY) announced Wednesday that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.
RTTNews | vor 143 Tagen
Eli Lilly Boosts FY24 Outlook - Update

Eli Lilly Boosts FY24 Outlook - Update

While reporting financial results for the first quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound and greater visibility into the company's production expansion for the remainder of the year.
RTTNews | vor 179 Tagen
Eli Lilly Q4 Results Top Estimates

Eli Lilly Q4 Results Top Estimates

Drugmaker Eli Lilly reported Tuesday a profit for the fourth quarter that grew 13 percent from last year, reflecting strong Mounjaro sales and higher realized prices. Both adjusted earnings per share and revenues topped analysts' expectations. The company also provided strong revenue guidance for the full-year 2024.
RTTNews | vor 263 Tagen
Tools
Wirtschaftskalender
Market Hours
Interest Rates
Holidays Calendar
Forex-Markt
Forex-Volatilität
Forex-Korrelation
Forex-Nachrichten
forex analysis
COT-Daten
Liquidität
Forex-Rechner
Forex Heat-Map
Indicators Heatmap
Community
Community
Systeme
Beliebteste Systeme
Strategien
Wettbewerbe
Forex-Charts
Forex-Sentiment
Prognoseindikator
Bewertungen
Broker
Prop Trading Firms
VPS-Dienste
Signalanbieter
EA Programmierdienstleistungen
Affiliate Programs
PAMM - Broker-Dienstleistungen
Rabattprogramm-Dienstleistungen
Handelsplattformen
Expertenberater
Krypto-Börsen
Trading Courses
Broker
Forex-Spreads
Forex-Broker-Kotierungen
Forex-Broker-Swaps
Volumen des Forex-Brokers
Forex-Broker-Aktionen Broker News
Plattform
Widgets
Funktionen
API
RSS
Stock Portfolio
Affiliate Software
Erweiterte Charts
Betreuung
FAQ
Hilfe
Kontaktieren Sie uns
Fehler melden!
Über uns
Blog
© 2024 Myfxbook Ltd. Alle Rechte vorbehalten.
WARNUNG VOR HOHEM RISIKO: Der Devisenhandel birgt ein hohes Risiko, das möglicherweise nicht für alle Anleger geeignet ist. Der Einsatz von Leverage schafft zusätzliches Risiko und Verlustgefahr. Bevor Sie sich für den Devisenhandel entscheiden, sollten Sie Ihre Anlageziele, Ihr Erfahrungsniveau und Ihre Risikotoleranz sorgfältig prüfen. Sie könnten Ihre ursprüngliche Investition teilweise oder ganz verlieren. Investieren Sie kein Geld, das Sie sich nicht leisten können, zu verlieren. Informieren Sie sich über die mit dem Devisenhandel verbundenen Risiken und lassen Sie sich von einem unabhängigen Finanz- oder Steuerberater beraten, wenn Sie Fragen haben. Alle Daten und Informationen werden ausschließlich zu Informationszwecken bereitgestellt und sind nicht für Handelszwecke oder Beratung gedacht. Die vergangene Performance ist kein Indikator für zukünftige Ergebnisse.